Biogen (BIIB) Non-Current Deferred Tax Liability (2016 - 2025)
Historic Non-Current Deferred Tax Liability for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $507.6 million.
- Biogen's Non-Current Deferred Tax Liability rose 16645.67% to $507.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $507.6 million, marking a year-over-year increase of 16645.67%. This contributed to the annual value of $507.6 million for FY2025, which is 16645.67% up from last year.
- Per Biogen's latest filing, its Non-Current Deferred Tax Liability stood at $507.6 million for Q4 2025, which was up 16645.67% from $358.1 million recorded in Q3 2025.
- Biogen's Non-Current Deferred Tax Liability's 5-year high stood at $966.7 million during Q1 2021, with a 5-year trough of $118.3 million in Q2 2025.
- Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $539.4 million (2022), whereas its average is $513.7 million.
- Per our database at Business Quant, Biogen's Non-Current Deferred Tax Liability skyrocketed by 31042.39% in 2024 and then plummeted by 7996.95% in 2025.
- Biogen's Non-Current Deferred Tax Liability (Quarter) stood at $694.5 million in 2021, then crashed by 51.81% to $334.7 million in 2022, then soared by 91.75% to $641.8 million in 2023, then crashed by 70.32% to $190.5 million in 2024, then surged by 166.46% to $507.6 million in 2025.
- Its Non-Current Deferred Tax Liability was $507.6 million in Q4 2025, compared to $358.1 million in Q3 2025 and $118.3 million in Q2 2025.